

Ad
cont'd

(iv) capable of specifically binding FK-506, rapamycin, or pharmacologically active metabolites or derivatives thereof, but not cyclosporins.

Cancel claims 2 and 3.

REMARKS

Substitute p. 29 is required by the USPTO's Raw Sequence Listing Error report.

Claim 1 is amended solely to comport with the USPTO's rules of sequence listing.

The Office is respectfully requested to enter these changes.

Date

06/05/2002

Respectfully submitted,



Dr. Melvin Blecher
Attorney for Applicant
Reg. No. 33,649

Law Offices of Dr. Melvin Blecher
4329 Van Ness St., NW
Washington, DC 20016-5625
T 202 363 3338
F 202 362 8404